Carisoprodol

1. 2026-10-19issueIssued info_card
2. 2026-10-02srcMuscle relaxants for non-specific low-back pain
3. 2026-10-02srcRisk of Opioid Overdose Associated With Concomitant Use of Opioids and Skeletal Muscle Relaxants: A Population-Based Cohort Study
4. 2026-10-02srcCYP2C19 genetics in fatal carisoprodol intoxications
5. 2026-10-02srcCarisoprodol tolerance and precipitated withdrawal
6. 2026-10-02srcAssessment of direct gating and allosteric modulatory effects of meprobamate in recombinant GABA(A) receptors
7. 2026-10-02srcCarisoprodol: an underrecognized drug of abuse in north India
8. 2026-10-02srcSevere Carisoprodol Withdrawal After a 14-Year Addiction and Acute Overdose
9. 2026-10-02srcComparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review
10. 2026-10-02srcAssessment of subunit-dependent direct gating and allosteric modulatory effects of carisoprodol at GABA(A) receptors
11. 2026-10-02srcCharacterizing the subjective and psychomotor effects of carisoprodol in healthy volunteers
12. 2026-10-02srcPostmortem carisoprodol and meprobamate concentrations in blood and liver: lack of significant redistribution
13. 2026-10-02srcCarisoprodol Therapy and CYP2C19 Genotype
14. 2026-10-02srcMultidrug toxicity involving sumatriptan
15. 2026-10-02srcThe Pharmacology and Toxicology of the 'Holy Trinity'
16. 2026-10-02srcCarisoprodol use and abuse in Norway: A pharmacoepidemiological study
17. 2026-10-02srcA multi-drug intoxication fatality involving Xyrem (GHB)
18. 2026-10-02srcThe effect of scheduling and withdrawal of carisoprodol on prevalence of intoxications with the drug
19. 2026-10-02srcTHE HISTORY, CHEMISTRY, AND PHARMACOLOGY OF CARISOPRODOL
20. 2026-10-02srcCarisoprodol-Mediated Modulation of GABAA Receptors: In Vitro and in Vivo Studies
21. 2026-10-02srcA Single Amino Acid Residue at Transmembrane Domain 4 of the Alpha Subunit Influences Carisoprodol Direct Gating Efficacy at GABAA Receptors
22. 2026-10-02srcCarisoprodol poisoning with serotonin toxicity
23. 2026-10-02srcComparative Risk of Opioid Overdose With Concomitant Use of Prescription Opioids and Skeletal Muscle Relaxants
24. 2026-10-02srcCommonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone
25. 2026-10-02srcCarisoprodol intoxications and serotonergic features
26. 2026-10-02srcCarisoprodol intoxications: a retrospective study of forensic autopsy material from 1992-2003
27. 2026-10-02srcDouble-blind, placebo-controlled trial of carisoprodol 250-mg tablets in the treatment of acute lower-back spasm
28. 2026-10-02srcRole of drug testing as an early warning programme: the experience of the Republic of Korea
29. 2026-10-02srcCarisoprodol as a drug of abuse
30. 2026-10-02srcMeprobamate dependence secondary to carisoprodol (Soma) use
31. 2026-10-02srcFormation of meprobamate from carisoprodol is catalysed by CYP2C19
32. 2026-10-02srcCarisoprodol: A drug of continuing abuse
33. 2026-10-02srcDailyMed: CARISOPRODOL Prescribing Information
34. 2026-10-02srcACMD Report: A Review of the Evidence on the Use and Harms of Carisoprodol
35. 2026-10-02srcSchedules of Controlled Substances: Placement of Carisoprodol Into Schedule IV
36. 2026-09-04issueIssued emergency
37. 2026-09-04issueIssued info_card
38. 2026-09-04issueIssued notice
39. 2026-06-04proposal35 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
40. 2026-06-04publicationPublication — backfill
41. 2026-05-12revisionRevision 1
42. 2026-05-12genGeneration — pipeline-v5 · with 3 morepipeline-v5
43. 2026-05-12rungeneration run

The same entries, as forms: six forms.